LAWRENCE JEFFREY GREEN, MD

Lawrence J Green, MD LLC
9601 Blackwell Road Suite 260
Rockville, MD 20850
(301) 610-0663
Current Affiliation: Private Practice 1997- Present

Faculty Appointment:

George Washington University School of Medicine 1996 - Present
Department of Dermatology
Clinical Professor

Postgraduate Education:

Residency:	University of California at Irvine Medical Center Orange, California Specialty: Dermatology	1992 - 1995
Fellowship:	University of California at Irvine School of Medicine Irvine, California Specialty: Dermatology Research	1990 - 1992
Internship:	Westchester County Medical Center New York Medical College Valhalla, New York Specialty: Internal Medicine	1989 - 1990

Education:

Graduate:	New York Medical College Valhalla, New York Degree: Doctor of Medicine	1985 - 1989
College:	University of Michigan Ann Arbor, Michigan Degree: Bachelor of Arts in Honors English	1981 - 1985

Licensure:

●	Commonwealth of Virginia Board of Medicine Number: 052221	Current
●	Maryland Board of Quality Assurance Number: D0050346	Current
●	District of Columbia Board of Medicine Number: 21660	Current

- California State Board of Medical Quality Assurance — Current
  Number: G 069239
- United States Drug Enforcement Agency — Current
  Number: BG 2471869

Certification:

- American Board of Dermatology — 1995, 2005, 2014
- Laser Dermatology Preceptorship — 1993
  Beckman Laser Institute, Irvine, CA
- National Board of Medical Examiners, Part III — 1990
- Basic Life Support "health care provider" — Current
  American Heart Association
- Advanced Cardiac Life Support — 2000-2008
  American Heart Association

Awards and Citations:

- Presidential Citation — 2023
  American Academy of Dermatology
- Outstanding Clinician of the Year Award — 2019
  National Psoriasis Foundation
- Advocate of the Year Award — 2018
  American Academy of Dermatology
- Presidential Citation — 2017
  American Academy of Dermatology
- Presidential Citation — 2017
  American Academy of Dermatology
- Patient Safety Hero Award
  American Society for Dermatologic Surgery — 2015
- Presidential Citation — 2011
  American Academy of Dermatology
- Senatorial Citation for Advancing Patient Safety — 2011
  Senate of France
- President's Council on Volunteerism and Civil Service — 2010
  President Obama
- President's Award — 2009
  American Society for Dermatologic Surgery

Professional Societies:

●	American Dermatological Association	2020- Present
●	Noah Worcester Dermatology Society	2016 – Present
●	Women's Dermatologic Society	2016- Present
●	American Society for Dermatologic Surgery	2000 - Present
●	District of Columbia Dermatologic Society	1995 - Present
●	National Psoriasis Foundation Professional Member	1994 - Present
●	Montgomery County Medical Society/Med Chi	1998 - Present
●	American Academy of Dermatology	1992 - Present
●	California State Medical Society	1992 - 1995
●	New York State Medical Society	1985 - 1990
●	American Medical Student Association	1985 – 1989

Professional Activities:

●	Member, Council on Education American Academy of Dermatology	2023-
●	DSMB Chair, National Institute of Health (NIH) A Randomized, Double Blinded Comparison between Spironolactone and Doxycycline in Women with Acne Vulgaris	2022-
●	Member, Board of Directors National Psoriasis Foundation	2022-
●	Board Member American Academy of Dermatology	2019-2023
●	Benefactor Committee Chair Noah Worcester Dermatology Society	2022-
●	President Montgomery County Medical Society	2019-2020
●	Board Member American Society for Dermatologic Surgery	2016-2019
●	Online Section Editor The Dermatologist	2018-

- Medical Board Member — 2016-2022
  National Psoriasis Foundation
- Digital Editorial Board Member — 2016-
  Cutis
- Member, GAHPP Council — 2015-2020
  American Academy of Dermatology
- Chair, SkinPAC Board of Advisors — 2015-2017
  American Academy of Dermatology
- Vice Chair, SkinPAC Board of Advisors — 2014-2015
  American Academy of Dermatology
- Member, MOHs workgroup — 2014-2016
  American Academy of Dermatology
- President Elect — 2017-2018
  Montgomery County Medical Society
- Treasurer, Executive Board Member — 2014-2017
  Montgomery County Medical Society
- DSMB Safety Officer, National Institute of Health (NIH) — 2014-2017
  A Randomized Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamics, and Clinical Efficacy of ILV-094 (an anti IL-22 antibody) Administered Intravenously to Subjects with Atopic Dermatitis
- Editorial Board Member — 2013-
  Journal of Aesthetic and Clinical Dermatology
- Member, State Policy Committee — 2013-2019
  American Academy of Dermatology
- Chair, Policy Priorities Committee
  American Society for Dermatologic Surgery — 2011-2017
- Chair, Scope of Practice Committee
  American Society for Dermatologic Surgery — 2008- 2010
- Member**,** SkinPAC board of advisors — 2008-2017
  American Academy of Dermatology
- Vice President — 2017-2018
  Montgomery County Medical Society
- Chair, Legislative Committee
  Montgomery County Medical Society — 2010- 2018
- Committee Member-Coding and Reimbursement Committee — 2009- 2012
  American Academy of Dermatology

●	Committee Member-Scope of Practice American Society for Dermatologic Surgery	2008- 2010
●	Member, Board of Trustees-National Psoriasis Foundation	2005- 2014
●	Chair, Research Committee-National Psoriasis Foundation	2005- 2014
•	Committee Member - Public Relations Committee American Society for Dermatologic Surgery	2004-2007
•	Committee Member – Task Force on Branding American Society for Dermatologic Surgery	2003 -2006
●	Member, Psoriasis Expert Resource Group American Academy of Dermatology	2003 – 2005
●	Committee Member – Healthcare Finance Committee American Academy of Dermatology	2002 – 2007
●	Medical Advisor for Washington DC area Network National Psoriasis Foundation	1996 - 1999
●	Committee member - Recertification Education Committee American Academy of Dermatology	1994 - 1996
●	Committee member - Task Force on Photobiology American Academy of Dermatology	1993 - 1995
●	Regional representative to Resident Physician's Section American Academy of Dermatology	1993 - 1995
●	California Medical Association resident delegate and elected for state and national AMA meetings	1994
●	Advisor/organizing member for Orange County Network National Psoriasis Foundation	1992 - 1995

Bibliography:

- Efficacy and Safety of Microencapsulated Benzoyl Peroxide and Microencapsulated Tretinoin For the Treatment of Acne Vulgaris: Results From Two Phase 3 Double Blind, Randomized, Vehicle Controlled Studies
  James Del Rosso DO, Jeffrey Sugarman MD, Lawrence Green MD et al
  J Am Acad Dermatol 2023;89(4) 719-727

- Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5% in Rosacea: Results From Two Phase III Randomized, Vehicle Controlled Trials
  Neal Bhatia MD, Wm Philip Werschler MD, Hillary Baldwin MD, Jeffrey Sugarman MD, Lawrence J Green MD eta l
  J Clin Aesthet Dermatol 2023;16(8) 34-40

- Long Term Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5% in Rosacea: Results From an Extension of Two Phase III, Vehicle Controlled Trials
  William P Werschler MD, Jeffrey Sugarman MD, Neal Bhatia MD, Hillary Baldwin MD, Lawrence Green, MD et al
  J Clin Aesthet Dermatol 2023;16(8) 27-33

- Safety and Efficacy of Mirikizumab Versus Secukinumab and Placebo in the Treatment of Moderate to Severe Plaque Psoriasis (OASIS-2): A Phase 3, Multicentre, Randomised, Double Blind Sudy
  Prof Kim Papp, MD, Richard B Warren, MD, Prof Lawrence Green, MD et al
  Lancet Rheum 2023;5(9):E542-E552 DOI:https://doi.org/10.1016/S2665-9913(23)00120-0

- Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial
  Zirwas MJ, Draelos ZD, DuBois J, Kircik LH, Moore AY, Stein-Gold L, Alonso-Llamazares JJ, Bukhalo M, Bruce S, Eads K, Green LJ, et al
  JAMA Dermatol. 2023;159(6):613–620. doi:10.1001/jamadermatol.2023.0846

- Review of the Microbiome in Skin Aging and the Effect of A Topical Prebiotic Containing Thermal Spring Water
  Heather Woolery Lloyd MD, Anneke Andriesse PhD, Doris Day MD, Noelani Gonzalez MD, Lawrence Green MD, Elizabeth Grice PhD, Michelle Henry MD
  J Cosmet Dermatol 2023; 22: 96-102

- Efficacy and Safety of Apremilast in Patients With Mild-Moderate Psoriasis Up to 32 weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE trial
  LS Gold, K Papp, D Pariser, N Bhatia, H Sofen, L Albrecht, M Gooderham, KC Duffin, M Chen, M Paris, S Cheng, H Picard, Y Wang, L Green
  J Am Acad Dermatol 2023; 88(2): 429-430

- Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized controlled clinical trials
  Mark G. Lebwohl, MD; Leon H. Kircik, MD; Angela Y. Moore, MD; Linda Stein Gold, MD; Zoe D. Draelos, MD; Melinda J. Gooderham, MD; Kim A. Papp,MD, PhD; Jerry Bagel, MD; Neal Bhatia, MD; James Q. Del Rosso, DO; Laura K. Ferris, MD; Lawrence J. Green, MD; et al
  JAMA. 2022;328(11):1073-1084

- A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis
  A Pinter, LJ Green, J Selmer et al.
  J Eur Acad Dermatol Venereol, 2022; 36(2): 228-263

- Enhancing Topical Pharmacotherapy for Acne and Rosacea: Vehicle Choices and Outcomes
  Lawrence J Green, Edward Lain, Thomas Prunty, Robert Rhoades
  J Clin Aesthet Dermatol. 2022;15(4): 12-16

- Efficacy and Safety of Apremilast in Patients with Mild-to-Moderate Plaque Psoriasis: Results of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
  Linda Stein-Gold, Kim Papp, David Pariser, Lawrence Green et al
  Journal of the American Academy of Dermatology, 2022: 86 (1) 77–85

- Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials
  Kircik LH, Green L, Guenin E, et al.
  J Dermatolog Treat. 2021 Aug 30;1-9

- Tazarotene 0.045% Lotion For Moderate-to-Severe Acne Patients: Pooled Analysis by Age and Sex
  Lawrence J Green, James Q DelRosso, Emil A Tanghetti, Eric Guenin
  J Drugs Dermatol June 2021 20(6):608-615

- Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: An Analysis of Daxibotulinumtoxin A for Injection in the SAKURA program
  Cohen Joel L, Green Lawrence J, Beer Kenneth R et al
  Dermatol Surg April 2021 47(4):511-515

- A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dosed Calcipotriene and Betamethasone Diproprionate Cream
  Linda Stein Gold, Lawrence J Green, Sunil Dhawan et al
  J Drugs Dermatol April 2021 20(4): 420-425

- Improvements in Submental Contour Up to 3 years After ATX-101: Efficacy and Safety Follow-Up of the phase 3 REFINE Trials
  Shannon Humphrey, Joel Cohen, Ahish Bhatia, Lawrence J Green, et al
  Aesthetic Surgery Journal Feb 22, 2021 https://doi.org/10.1093/asj/sjab100

- Wet Wipe Applicators: Exploring the Future of Topical Drug Delivery
  Lawrence J Green
  Practical Dermatology Feb 2021, 18 (2), 38-40

- DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study Sabrina G. Fabi,* Joel L. Cohen,† Lawrence J. Green et al
  Dermatol Surg Jan 2021, 47: (1), 48-54

- Commentary on the Influence of Topical Anesthesia on Superficial Sensitivity: A Double Blind, Randomized, Placebo Controlled Study on 48 Healthy Subjects
  Lawrence J Green
  Dermatol Surg Dec 2020, 46 (12), 1599

- Advances in Psoriasis Therapy (guest editorial)
  Lawrence Green, MD
  The Dermatologist August 2020, S9

- Efficacy and Safety of topical Sofpironium Bromide Gel for the Treatment of Primary Axillary Hyperhidrosis: A Phase II, Randomized, Controlled, Double Blind Trial
  Brandon Kirsh MD, Stacy Smith MD, Joel Cohen MD, Janet DuBois MD, Lawrence Green MD
  J Amer Acad of Dermatol June 2020 82 (6): 1321-27

- Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials
  S. Hsu, L.J. Green, M.G. Lebwohl, J.J. Wu, A. Blauvelt and A. Jacobson
  British J Dermatol April 2020, 82 (4):880-88

- Long-term Safety and Efficacy of Topical Glycopyronnium Tosylate For the Treatment of Primary Axillary Hyperhidrosis: Post Hoc Pediatric Subgroup Analysis From a 44 Week Open-label Extension study
  Adelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al
  Pediatr Dermatol March 2020: 00, 1-8

- Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
  Lawrence Green MD, Jeffrey M. Weinberg MD, Alan Menter MD, et al
  J Drugs Dermatol Feb 2020: 19 (2): 138-143

- Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study
  David M Pariser, Lawrence J Green, Edward L Lain et al
  J Clin Aesthet Dermatol. 2019;12(11):E53–E62

- What does efficacy cost? Evidence for Relative Cost-Effectiveness from Biologic Therapies
  Jerry Bagel, Ted Lain, Lawrence Green
  Practical Dermatology Oct 2019: 62-65

- Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis
  Lawrence J Green, Paul Yamauchi, Leon Kircik
  J Drugs in Dermatol August 2019 18 (8): 776-786

- Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
  Linda Stein Gold, Edward Lain, Lawrence J Green, et al
  J Drugs Dermatol August 2019 18 (8): 815-820

- A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris.
  Tanghetti EA, Kircik LH, Green LJ, et al.
  J Drugs Dermatol Jun 2019 1;18(6):542-548

- Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of Efficacy and safety findings by age from two phase 3 randomized controlled trials
  Hebert AA, Glaser D, Green L et al
  Pediatr Dermatol 2019, 36:89-99

- Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-To-Severe Plaque Psoriasis
  Andrew Blauvelt, Lawrence J Green, Mark Lebwohl et al
  J Drugs Dermatol March 2019 18: 3, 297-299

- Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials
  DeeAnna Glaser, Adelaide Hebert, Alexander Nast, William Werschler, Lawrence Green et al
  J Am Acad of Dermatol January 2019 Vol 80:1, 128-138

- Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results of Two Phase III Randomized Controlled Trials.
  Lawrence J Green, Francisco Kordel, Fran E Cook-Bolden et al
  J Drugs in Dermatology October 2018 Vol 17:10, 1062-1069

- Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results From Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials
  Angela Moore, Lawrence J Green, Suzanne Bruce et al
  J Drugs in Dermatology September 2018; 17:9, 987-996

- Update on Oral Molecules. Lawrence J Green
  The Dermatologist September 2018

- Halobetasol 0.01%/ Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
  David Pariser, Lawrence J Green, Linda Stein Gold, et al
  J Drugs in Dermatology July 2018 17:7, 723-726

- Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment: Findings From The LIBERATE study
  K. Reich, M. Gooderham, A. Bewley, L. Green et al
  J European Acad Dermatol Venereol March 2018

- The Maze of Managed Care. Lawrence J Green
  The Dermatologist: September 2017; 20-22

- Scalp Seborrheic Dermatitis and Dandruff Treatment Using an Herbal and Zinc Pyrithione Based Shampoo and Scalp Lotion
  Deganit Shinar-Barak and Lawrence Green
  J of Clinical and Aesthetic Dermatology Jan 2018

- Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab
  A pooled analysis of data from 2 phase 3 clinical trials
  (AMAGINE-2 and AMAGINE-3)
  Andrew Blauvelt, Kim Papp, Mark Lebwohl, Lawrence J Green, et al
  J American Acad Dermatol August 2017

- Treatment of Seborrheic Dermatitis Using a Novel Herbal Based Cream
  Deganit Shinar-Barak, Rueben del Rio and Lawrence Green
  J Aesthetic and Clinical Dermatology April 2017

- Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment in the LIBERATE Study
  K Reich, M Goodfield, L Green et al.
  Poster Presented at Winter AAD meeting Orlando, FL March 2017

- DRM04 for the treatment of axillary hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 Phase 3 randomized controlled trials
  D Pariser, A Hebert, A Nast, WPWerschler, S Shideler, L Green et al
  Poster Presented at Fall Clinical Dermatology Las Vegas, NV and EADV Conference Oct. 2016

- Improvements in Redness and Flaking of Psoriasis Lesions With Brodalumab in the Randomized, Placebo-Controlled, Phase 3 AMAGINE Studies
  Paul Yamauchi,[1] Boni Elewski,[2] Leon Kircik,[3,4] Lawrence Green et al
  Presented at Maui Dermatology Conference February 2017

- Maintenance of clinical efficacy in moderate-to-severe plaque psoriasis: a 52-week Evaluation of brodalumab in three multicenter, double-blind studies of 4363 subjects
  K Papp, M Lebwohl, L Green, P Yamauchi et al
  Poster Presented at Fall Clinical Dermatology Las Vegas, NV October 2016

- Safety profile of brodalumab in patients with moderate-to-severe plaque psoriasis: a 52-Week Evaluation of Phase III studies
  Kim A Papp, Lawrence J Green, Paul S Yamauchi, et al.
  Poster Presented at Fall Clinical Dermatology Las Vegas, NV , October 2016

- Reich K,Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept, And placebo, in patients with moderate to severe plaque psoriasis: 52-week results from Phase 3b, randomized, placebo-controlled trial (LIBERATE).
  J Eur Acad Dermatol Venereol. Accepted manuscript. doi:10.1111/jdv

- Effect of Apremilast and Etanercept on Pruritus and Health-Related Quality of Life in Patients With Moderate to Severe Plaque Psoriasis: Results from the LIBERATE study
  Lawrence Green, Diamond Thaci, Zushoun Zhang, et al
  Poster Presented at American Academy of Dermatology Meeting Washington DC March 2016

- Safety of Apremilast and Etanercept Compared With Placebo in Patients With Moderate to Severe Psoriasis: Results From the LIBERATE study
  Melinda Gooderham, MD; Jennifer Soung, MD; Lawrence Green, MD; Matthias Augustin
  Poster Presented at ODAC meeting Orlando, FL January 2016

- Who Do You Prefer? A Study of Public Preferences for Health Care Provider Type in Performing Cutaneous Surgery and Cosmetic Procedures in the United States
  Haider K Bangash, Omar Ibrihimi, Lawrence J Green, et al
  Dermatol Surg 2012 38: 10, 1645-1651

- Evaluation of the Efficacy, Tolerability, and Safety of an Over the Counter Acne Regimen Containing Benzoyl Peroxide and Salicylic Acid in Patients with Acne
  Leon H Kircik MD, Lawrence J Green MD, Joseph Eastern MD et al
  J Drugs in Dermatology 2013; 12 (3): 259-264

- A multicenter double masked placebo-controlled study assessing patient satisfaction with bimotoprost ophthalmic solution 0.03% for increasing eyelash prominence
  Joel Cohen MD, Lawrence Green MD, Carrie Caulkins PhD et al
  J American Academy of Dermatology 2013; 68 (4)suppl: AB20

- Randomized, Controlled, Evaluator-Blinded Studies Conducted to Compare the Efficacy and Tolerability of 3 Over-the-Counter Acne Regimens in Subjects with Mild or Moderate Acne
  Lawrence J Green MD, Leon H Kircik MD ,and Jennifer Gwazdauskas MBA
  J Drugs in Dermatology 2013; 12 (2): 180-185

- Perceptions of Expertise in Cutaneous Surgery and Cosmetic Procedures: What Primary Care Physicians think
  Ibrahimi OA, Bangash H, Green, L et al.
  Dermatol Surg 2012 38: 10, 1645-1651

- The Tolerability Profile of Clindamycin 1%/Benzoyl Peroxide 5% Gel vs Adapalene 0.1% Benzoyl Peroxide 2.5% Gel for Facial Acne: Results of Two Randomized Single-Blind, Split face Studies
  Lawrence J Green, P Gonzalez
  J Clinical and Aesthetic Dermatology 2012 5: 5, 16-24

- Clinical Evidence for the Role of a Topical Anti-inflammatory Agent in Comedonal Acne: Findings from a study of Dapsone 5% gel in combination with Tazarotene 0.1% cream and Adapalene 0.1% gel in patients with acne vulgaris
  Emil Tanghetti, MD,[a] Sunil Dhawan, MD,[b] Lawrence Green, MD et al
  J Drugs in Dermatology July 2011

- The Fight for Scope of Practice Regulations for Cosmetic Medical Procedures
  Lawrence J Green, MD
  The Dermatologist 2012; 18: 11, 57-63

- Clinical evidence for the role of a topical anti-inflammatory agent in Comedonal acne: Findings From a study of Dapsone 0.5% gel in combination with Tazarotene 0.1% cream in Patients With Acne vulgaris
  Emil Tanghetti, Sunil Dhawan, Lawrence Green, et al
  Poster presented at Fall Clinical Dermatology Meeting October 2010

- Randomized Comparison of the safety and efficacy of Tazarotene 0.1% cream and Adapalene 0.1% gel in the treatment of patients with at least moderate acne vulgaris
  Emil Tanghetti, Sunil Dwuan, Lawrence Green et al
  J Drugs in Dermatology 5: 549-558 2010

- A Controlled Randomized Study of Pain Levels in Subjects Treated with Calcium Hydroxylapatite (Radiesse) Premixed with Lidocaine for Correction of Nasolabial Folds
  Ellen Marmur, Lawrence J Green, Mariano Busso
  Dermatol Surgery 36: 3, 309-315 2010

- Comparing a Novel Solubilized Benzoyl Peroxide Gel With Benzoyl Peroxide/Clindamycin: Final Data From a Multicenter, Investigator-Blind, Randomized Study
  Leon Kircik MD, Lawrence Green MD, Diane Thiboutot MD et al.
  J Drugs in Dermatology Sept 2009

- Comparing a Novel Solubilized Benzoyl Peroxide Gel with Benzoyl Peroxide/Clindamycin: Final Data From a Multicenter Investigator Blind Randomized Study
  Kircik L, Green L, Thibitot D, et al.
  Poster Presented at Summer American Academy of Dermatology meeting August 2008

- Acne Challenging Case: Optimizing Therapy in Adolescents
  Lawrence J Green
  Journal of Clinical and Aesthetic Dermatology 2:4; 20-22 (s), 2009

- Results from a Community-Based Trial of Combination Antimicrobial and Retinoid Therapy
  Lawrence J Green and Leon Kircik
  Poster presented at World Congress of Dermatology 2008

- Efficacy and tolerability of a Three Step Acne System Containing a Solubilized Benzoyl Peroxide Lotion Versus a Benzoyl Peroxide Combination Product
  Lawrence J Green and James Del Rosso
  J of Clinical and Aesthetic Dermatology 1:3; 16-20, 2008

- Moisturizer Use Enhances Facial Tolerability of Tazarotene 0.1% cream without Compromising Efficacy in Patients with Acne Vulgaris
  Tanghetti E, Dralos Z, Dhawan S, Gold M, Kircik L, Green L.
  Poster Presented at Hawaii Dermatology Seminar March 2008

- Efficacy and tolerability of a 3-step acne system containing a novel solubilized benzoyl Peroxide Lotion for normal to dry skin versus a benzoyl peroxide/clindamycin combination Product: An Investigator-blind, randomized, parallel-group study
  Lawrence J Green Poster. Presented at AAD Annual Meeting, San Antonio, TX 2008

- Rationale for Treating Acne with Combination Therapy Based on Clinical Trial Outcomes
  Lawrence J Green
  Skin & Aging August 2007

- Clinical benefit of using tazarotene+/- clindamycin-benzoyl peroxide adjunctively with minocycline in the treatment of acne vulgaris**.** Thibitot, D Leyden J Green, L et al.
  Poster presented at SDEF Hawaii Dermatology Seminar March 2007, Maui, HI

- Evidence-based results with topical retinoids for acne.
  Green L
  Skin & Allergy News 2005; September supplement:4-5,14.

- A Clinical Evaluation of Tazarotene 0.1% Gel with and without a High or Mid High Potency Steroid in Patients with Plaque Psoriasis
  Lawrence J. Green and Wendy Sadoff
  Journal of Cutaneous Medicine and Surgery Mar-Apr;6: 95-102, 2002.

- Are we teaching phototherapy? Results of an informal survey.
  Lawrence J. Green
  Photodermatology, Photoimmunology, and Photomedicine 15:39-40, 1999.
- The Dermatologist's Guide to Looking Younger.
  Lawrence J. Green
  Crossing Press, 1999.

- Are we teaching phototherapy? Results of a survey of phototherapy education.
  Lawrence J. Green (abs) in Advancing the science and art of teaching dermatology.
  Ponciano D. Cruz
  Archives of Dermatology 134: 858, 1998.

- Neurocutaneous melanosis and Dandy Walker syndrome in an infant.
  Lawrence J. Green, Vandana S. Nanda, Gerald M. Roth, Ronald J. Barr.
  International Journal of Dermatology 38: 366-373, 1997.

- Pityriasis rotunda in an elderly black American.
  Lawrence J. Green, Gary Cole, Edward WB Jeffes, Melissa Watcher.
  Journal of Geriatric Dermatology 2: 177-179, 1994.

- A comparison study of 7.5% lactic acid cream and 12% lactic acid lotion in psoriatic patients with xerosis cutis.
  Lawrence Green and Gary Cole.
  Cosmetic Dermatology 7: 44-45, 1994.

- Photoaging and the Skin: The Effects of Tretinoin.
  Lawrence J. Green, Allison McCormick, and Gerald D. Weinstein.
  Dermatologic Clinics 11: 97-105, 1993.

- New topical Retinoid gel for therapy of psoriasis: Dose ranging study of AGN 190168.
  G.D. Weinstein, L. Green, L.A. Drake, et al.
  Journal of Investigative Dermatology (abs) 100: 544, 1993

- Effectiveness of nucleic acid inhibitors on psoriatic plaques.
  L. Green, J. McCullough, A. McCormick, E.W. Jeffes, and G. Weinstein.
  Journal of Investigative Dermatology (abs) 98: 602, 1992.

- Methotrexate (MTX) therapy of psoriasis: An in vitro model examining the effect of a 24-hour pulse on the growth and proliferation of lymphoid cells and keratinocytes.
  E.W. Jeffes, J. McCullough, A, McCormick, J. Dube, M. Dang, L. Green, and G. Weinstein.
  Journal of Investigative Dermatology (abs) 98: 592, 1992.

- Immunologic Abnormalities in autoimmune chronic active hepatitis.
  Lin RY, Green LJ, and Winny A.
  Journal of Rheumatology 16: 1489-93, 1989.

- Immunologic abnormalities in autoimmune chronic active hepatitis.
  Lin RY, Green LJ, and Winny A.
  Clinical Research (abs) 36: 794A, 1989

FDA Presentations:

- Safety and efficacy of ATX-101 to treat submental fullness
  FDA DODAC committee hearing on ATX-101 March 2015

- Safety and efficacy of Radiesse to improve aging hands
  Presented on behalf of ASDS to FDA Committee on Plastic Surgical Devices Feb 2015

- Safety and efficacy of secukinamab to treat moderate to severe plaque psoriasis
  Presented on behalf of National Psoriasis Foundation to FDA DODAC committee Jan 2015

- Safety and efficacy of Juvéderm Voluma to improve aging cheeks
  Presented on behalf of ASDS to FDA Committee on Plastic Surgical Devices March 2014

- The dangers of indoor tanning
  Presented on behalf of the AAD at FDA hearing on indoor tanning Oct 2011

CME Presentations:

- Aesthetic Clinical Tips
  Fall Clinical Dermatology Conference Las Vegas, NV October 2023

- Clinical Trial Primer
  SkinSanity Conference Phoenix, AZ October 2023

- Topical and Oral Therapy Update for Psoriasis
  National Psoriasis Foundation Resident Conference Washington DC October 2023

- Botulinum Toxin Clinical Trial Update
  Florida Society For Dermatologic Surgery Meeting Del Ray Beach, FL October 2023

- Hyperhidrosis Update
  SCALE Meeting Nashville, TN May 2023

- Upcoming Topical Therapies
  SCALE Meeting Nashville, TN May 2023

- Hormones in Acne and Hair Loss
  Session Moderator/Speaker
  American Academy of Dermatology Winter Meeting New Orleans March 2023

- Clinical Tips for Aesthetic Dermatology
  Winter Clinical Dermatology Conference Kona, HI January 2023

- New Treatments for Hyperhidrosis
  Cosmetic Surgery Forum Nashville December 2022

- American Academy of Dermatology Update
  Cosmetic Surgery Forum Nashville December 2022

- Climate Change in Dermatology Pro vs Con
  American Academy of Dermatology Winter Meeting Boston March 2022

- Hormones in Acne and Hair Loss
  Session Moderator/Speaker
  American Academy of Dermatology Winter Meeting Boston March 2022

- Sunscreen Regulatory Update
  Cosmetic Surgery Forum Nashville December 2021

- Botulinum Toxin Trials Update
  Cosmetic Surgery Forum Nashville December 2021

- The Skin Microbiome in Atopic Dermatitis
  Fall Clinical Conference Las Vegas October 2021

- Botulinum Toxin Clinical Trial Update
  Fall Clinical Dermatology Conference Las Vegas October 2021

- New Aesthetic Injectables
  Noah Worcester Dermatology Society Meeting Indianapolis June 2021

- Implications of the 2020 Election for Dermatologists
  Fall Clinical Dermatology Conference November 2020

- New treatments for buttocks cellulite
  Israel Society for Dermatologic Surgery Annual Meeting Tel Aviv, Israel Dec 2019

- Update on Clinical Therapeutics
  Noah Worcester Dermatology Meeting Palm Springs, CA April 2019

- American Society for Dermatologic Surgery Association Update
  Kansas Society for Dermatology Meeting Lawrence, KS August 2018

- Oral Therapies for Psoriasis
  American Academy of Dermatology Summer Meeting Chicago, IL July 2018

- American Academy of Dermatology Association Update
  Noah Worcester Dermatology Society Annual Meeting, Savannah, GA March 2018

- Topical Acne Therapies
  American Academy of Dermatology Annual Meeting, San Diego, CA Feb 2018

- Rosacea Update
  American Academy of Dermatology Annual Meeting San Diego, CA Feb 2018

- Acne Expert Tips
  Winter Clinical Dermatology Meeting Maui, HI Jan 2018

- Update in botulinum Toxin Therapy
  Israel Society for Dermatologic Surgery Annual Meeting Dec 2017

- New Treatments for Hyperhidrosis
  Israel Society for Dermatologic Surgery Annual Meeting Dec 2017

- Acne Therapy Update
  New York Society for Dermatologic Surgery Meeting Nov 2017

- Expert Medical and Surgical Tips
  Fall Clinical Dermatology Meeting Oct 2017

- Acne and Rosacea Therapeutic Update
  Florida Society for Dermatology Meeting June 2017

- What is Affecting Dermatologist Payments?
  Winter Clinical Dermatology Conference Jan 2017

- ATX-101(Kybella) for the reduction of submental fat: Clinical trial results
  Israeli Society for Dermatologic Surgery Annual Meeting, December 2014

- Congressional Capitol Hill Briefing on Psoriasis
  Presented on behalf of the National Psoriasis Foundation September 2014

- A multicenter double masked placebo-controlled study assessing patient satisfaction with bimotoprost ophthalmic solution 0.03% for increasing eyelash prominence. Lawrence J Green Poster (P6806)
  Presented at 2013 American Academy of Dermatology Annual Meeting
- Update on Consumer Acne Market. Lawrence J Green
  Presented at Orlando Dermatology and Aesthetic Conference January 2011

- How to Build a Cosmeceutical Dispensing Practice. Lawrence J Green
  Presented at Orlando Dermatology and Aesthetic Conference January 2011

- Optimizing Acne Therapy**.** Lawrence J Green
  Presented at Fall Clinical Dermatology Conference Las Vegas, NV Oct 19, 2008

- Cosmeceutical Update and Acne Update. Lawrence J Green
  Presented at Coastal Dermatology Meeting Carmel, CA Oct 2008

- Update on phototherapy**.** Lawrence J Green
  Presented at AAD meeting in the Psoriasis Symposium, July 2005

- Noninvasive Management of the Aging Face**.** Lawrence J Green
  Presented at Carolina Dermatology Winter Meeting, January 2004

- New Biologic Therapies for Psoriasis. Lawrence J Green
  Presented at Georgetown University Grand Rounds, George Washington University, and dinner meetings in Baltimore and Washington DC, September 2003-February 2004

- Safety of Tacrolimus 0.03 ointment in the pediatric and adult population in the treatment of atopic dermatitis . Lawrence J Green
  Presented at Hawaii Dermatology Seminar, February 2003

- Rationale for allowing reimbursement for XTRAC laser therapy for psoriasis and other inflammatory skin disease. Lawrence J. Green
  Presented before the RUC committee of CMS, April 2002

- A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Tolerability of Treating Facial Acne Vulgaris Once Daily With Tazarotene 0.1% Gel or Adapalene 0.1% Gel
  A Shalita, G Webster, N Lowe, B Miller, B Solomon, L Guenther, K Loven, L Green, Y Poulin
  Presented at American Academy of Dermatology Meeting, Washington DC, March 2001

- Is there a cure for wrinkles? Lawrence J. Green.
  Presented at Shady Grove Hospital, October 5, 1998

- The differential diagnosis of hair loss. Lawrence J. Green
  Presented at Fairfax Hospital Department of Medicine Grand Rounds, June 25, 1998

- Psoriasis: Topical therapeutic alternatives. Lawrence J. Green
  Presented at Tidewater Dermatologic Society meeting January 24, 1999, Columbus Dermatologic Society meeting December 6, 1998, and Orlando Dermatologic Society meeting June 3, 1998

- Is there a cure for wrinkles? Lawrence J. Green
  Presented at Fairfax Hospital, May 19, 1998

- Are we teaching photomedicine? Lawrence J. Green
  Presented at Professors of Dermatology Meeting, Orlando, March 1, 1998

- Are we teaching photomedicine? Lawrence J. Green.
  Presented at annual Photomedicine Society Meeting, Orlando, February 26, 1998

- Psoriasis: Topical therapeutic alternatives. Lawrence J. Green.
  Presented at Jacksonville Dermatology Society Meeting, October 26, 1997

- Psoriasis. Lawrence J. Green.
  Presented at Univ. of Virginia, Department of Dermatology Grand Rounds, September 4, 1997

- Psoriasis: Topical therapeutic alternatives. Lawrence J. Green.
  Presented at dermatologist meetings in Baltimore, Raleigh, Albany,
  Rochester, Kansas City, Tampa, Jacksonville, Wilmington, Knoxville, Cincinnati, Dayton, St. Louis, Minneapolis, Tulsa, Omaha, and Philadelphia from August 1997-Present

- Psoriasis. Lawrence J. Green
  Presented at George Washington University and Washington Hospital Center Department of Dermatology Resident teaching conference, February 5, 1997

- Rejuvenate Your Skin Seminar. Lawrence J. Green and Larry McNelly.
  Presented at Alexandria Hospital, February 1997

- Psoriasis. Lawrence J. Green
  Presented at Department of Medicine Grand Rounds (Fairfax Hospital and Arlington Hospitals) February 1996

- Pityriasis Rotunda in a Black American with W. African ancestors. Lawrence J. Green.
  Presented at Advanced Seminars in Dermatology meeting August 1993

- New topical Retinoid gel for therapy of psoriasis: Dose ranging study of AGN 190168.
  G.D. Weinstein, L. Green, L.A. Drake, et al.
  Presented at Society of Investigative Dermatology meeting April 1993

- Effectiveness of intralesional nucleic acid inhibitors on psoriatic plaques.
  L. Green, J. McCullough, A. McCormick, E.W. Jeffes, A. Korey, E. Orenberg, and G. Weinstein.
  Presented at Society of Investigative Dermatology meeting, April 1992

- Methotrexate (MTX) therapy of psoriasis: An in vitro model examining the effect of a 24-hour MTX pulse on the growth and proliferation of lymphoid cells and keratinocytes. E.W. Jeffes, J.
  Presented at Society of Investigative Dermatology meeting April 1992

- Porphyrin affinity towards serum lipoproteins in patients with protoporphyria and porphyria cutanea tarda. Lawrence Green and Maureen Poh-Fitzpatrick.
  Presented at New York Medical College Student Research Forum June 1989

- Immunologic abnormalities in autoimmune chronic active hepatitis. Lin RY, Winny A, and Green LJ.
  Presented at American Federation of Clinical Research Conference-Eastern Section October 1988

Investigational Research:

- A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR)
  August 2021-June 2022

- A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacyof ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
  August 2021-July 2022

- A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis
  May 2021-present

- A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
  April 2021-present

- An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating. (+ An Evaluation of Skin pH for a Subset of Subjects Treated in the Sahara Study)

March 2021-December 2021

- A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects with Axillary Hyperhidrosis (the "Cardigan I Study")
  November 2020-October 2021

- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial To Evaluate The Efficacy And Safety of FB-401 In Children, Adolescent And Adult Subjects (Ages 2 Years And Older) With Mild to Moderate Atopic Dermatitis
  October 2020-November 2021

- A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
  Sep 2020-November 2021

- A Multi-Center, Randomized, Double- Blind, Placebo Controlled Study To Compare Efficacy and Safety of Trifarotene (CD5789) Cream When Used with an Oral Antibiotic for the Treatment of Severe Acne Vulgaris
  Aug 2020- present

- A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects with Chronic Hand Eczema
  Jul 2020-October 2021

- A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis
  May 2020-present

- A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
  March 2020-July 2021

- A Phase 3, Multicenter, Open-Label, Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302
  March 2020-October 2021

- A Phase 3, 8 Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
  December 2019-February 2021

- A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults.
  February 2020-July 2021

- A Phase 2 Efficacy and Safety Study of Tapinarof for the treatment of Plaque Psoriasis in Adults.
  October 2019-Sep 2020

- A Multi-Center, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis
  August 2019-present

- A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Mild-to-Moderate Plaque Psoriasis.
  May 2019-Oct 2020
- A Phase 3 Open Label Safety Study of A-101 Topical Solution for The Treatment of Common Warts.
  March 2019-Feb 2020
- A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-Severe Plaque Psoriasis.
  January 2019-Feb 2020
- A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris
  January 2019-Dec 2019
- A Multi-Center, Randomized, Open-Label, Phase 3 Long-Term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects with Axillary Hyperhidrosis
  October 2018-March 2020
- A phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied Twice A Week in Subjects with Common Warts
  September 2018- Jan 2020
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled study comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in patients with Moderate-to-Severe plaque psoriasis
  Jun 2018-May 2020
- A randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects with Pruritus Associated with Psoriasis Vulgaris
  Mar 2018-Mar 2019
- A randomized, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream compared to MC2-01 Cream Vehicle and Active Comparator in subjects with mild-to-moderate Psoriasis Vulgaris.
  Aug2017-April 2018
- An Open Label Multicenter Trial To Assess the Safety of Single Repeat Treatment of Daxibotulinum Toxin A For Injection For Treatment of Moderate to Severe Glabellar Lines
  Dec 2016-2018
- A Multicenter Evaluation of the Safety and Efficacy of Sarecycline Tablets in the Treatment of Acne Vulgaris
  January 2015-2017
- A Randomized Double-Blind Placebo Controlled Parallel Group Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinamab (300 mg) as Assessed by the Psoriasis Scalp Severity Index at 12 Weeks of Treatment Compared to Placebo March 2015-2017

- A Multicenter Randomized Double Blinded Placebo Controlled Study Evaluating the Safety And Efficacy of LIPO-22 for the Reduction of Central Abdominal Bulging Due to Abdominal Fat In Non-Obese Subjects
  May 2015-2016

- A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
  April 2014-2015

- Efficacy and Safety of Ingenol mebutate gel 0.06% when applied once daily for 2,3, or 4 Consecutive Days to a treatment area of approximately 250 cm2 on trunk and extremities In Subjects with Actinic Keratosis
  April 2014-August 2014

- A safety and efficacy study to compare Dapsone Dermal Gel with Vehicle Control in Patients With Acne Vulgaris
  January 2014- January 2015

- A Randomized double-blind vehicle controlled parallel group study of the safety of Betamethasone Diproprionate Spray 0.05% versus Diprolene Lotion 0.05% and the efficacy Of Betamethasone Diproprionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis
  December 2013-December 2015

- Phase 3b, multicenter, randomized, placebo controlled double blind, double-dummy, study Of the efficacy and safety of Apremilast (CC-10004), Etanercept, and Placebo in subjects with moderate to severe plaque psoriasis
  January 2013-2014

- A Phase 3 Study to evaluate the efficacy and safety of induction and maintenance regimens of Brodalumab compared with placebo and ustekinumab in subjects with moderate to severe Plaque Psoriasis: AMAGINE-2
  December 2012-2016

- A Double Blind, Randomized, Parallel-Group, Vehicle Controlled Multicenter Study Comparing Adapalene 0.1% and Benzoyl Peroxide 2.5% Generic to Reference Listed Drug In the Treatment Of Acne Vulgaris
  October 2012- March 2013

- Multicenter randomized double-blind placebo-controlled Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area
  February 2012-December 2012

- A Phase 3 randomized, Double-blind, 12 Week Vehicle Controlled Parallel Group Study Assessing the Efficacy and Safety of CD5024 1% Cream versus Vehicle Cream in Subjects with Papulo-Pustular Rosacea
  February 2012-December 2012

- A Multicenter, Double-Masked, Placebo Controlled Study Assessing Patient Satisfaction with LATISSE for Increasing Eyelash Prominence
  November 2011- February 2012

- An Open Label, 12 Week Study to Evaluate the Safety and Efficacy of the MaxClarity System in Subjects with Acne
  June-October 2011

- A Non-Inferiority Study Comparing Aczone Gel 5% and Differin 0.3% Gel Dual therapy to Dual Therapy with Duac Topical Gel and Differin 0.3% Gel for the Treatment of Facial Acne Vulgaris
  Oct 2010-February 2011

- A national, multi-center, prospective, randomized, double blind, 4 arm, parallel group, 8 Week study in subjects with psoriasis vulgaris on the non-scalp regions of the body
  November 2010-February 2011

- Comparative Efficacy and Safety of Tazaorac0.1% facial cream and Differin 0.3% gel in the Treatment of moderate to severe facial acne vulgaris
  Jan-July 2009

- A single-blind randomized comparative split-face study evaluating the tolerability of Duac Topical Gel to Epiduo in the treatment of acne vulgaris
  Sept 2009-Dec 2009

- A randomized, single-blind controlled split face study to evaluate and compare the efficacy and safety of Maxclarity and Proactive in subjects with acne
  Sept 2009-Dec 2009

- An Evaluation of Pain with the use of Lidocaine-Mixed Radiesse for the Treatment of Nasolabial Folds
  October-November 2008

- A Multi-Center, Investigator Blinded Randomized Study to Evaluate the Tolerability and Efficacy of Clenziderm MD vs. Benzaclin Topical Gel in the Treatment of Moderate Facial Acne Vulgaris
  May-September 2008

- Comparative Efficacy and Safety of Tazorac 0.1% cream and Differin 0.3% gel in the Treatment of Moderate to Severe Acne Vulgaris
  November 2007-April 2008

- An Investigator blinded, randomized study to evaluate the tolerability and efficacy of CLENZIderm MD (normal to dry skin) vs Duac topical gel in the treatment of mild to moderate facial acne vulgaris
  March-June 2007

- Comparative tolerability and efficacy of tazorac 0.1% cream and Retin-A Micro 0.04% in the Treatment of mild to moderate facial acne vulgaris
  December-June 2007

- Combined effects of Duac topical gel with Retin-A 0.025 gel compared to triple therapy with 1% clindamycin gel, Retin-A 0.025 gel and 5% benzoyl peroxide wash in the treatment of acne vulgaris
  November 2006-March 2007

- Community based evaluation of combination therapy using Duac Topical Gel and a topical retinoid in the treatment of moderate to severe acne vulgaris
  September 2006-December 2006

- Observational safety surveillance study utilizing Enbrel to treat psoriasis: A 5-year commitment
  May 2006-June 2011

- A comparison of the tolerability and efficacy of tazorac 0.1% cream used in combination with minocycline versus the combination of tazorac 0.1% cream and duac topical gel versus minocycline alone for the treatment of moderate to severe acne vulgaris
  Sept. 2005-Jan. 2006

- A pilot study comparison initiating treatment with either Duac Topical gel, Differin 0.1% gel, or both for 4 weeks followed by either combination therapy or Differin0.1% gel alone for the treatment of acne vulgaris for 8 additional weeks Duac gel with and without adapalene 0.1% gel in the treatment of facial acne vulgaris
  Sept. 2005-Jan 2006

- An evaluation of the efficacy of tacrolimus 0.03% ointment versus placebo in adults with mild-moderate atopic dermatitis.
  December 2001-April 2002

- An evaluation of the safety and efficacy of Tazorac 0.1% gel and Differin 0.1% gel in the treatment of subjects with facial acne vulgaris.
  July 1999-January 2000

- Tazorac 0.1% observation study in stable plaque psoriasis.
  October 1997-April 1998.

- A double-blind evaluation of topical methotrexate in combination with dipyrimadole in subjects with plaque psoriasis.
  July-October 1993

- A double blind, bilateral comparison study of two topical retinoic acid (tretinoin) cream formulations and a vehicle control on patients with psoriasis.
  March-June 1992

- A randomized, double blind vehicle-controlled study of topical clobetasol gel 0.05% in the treatment of moderate to severe plaque psoriasis.
  April-June 1992

- Double blind bilateral paired comparison study of Penecare 7.5% cream vs. 12% Lac-Hydrin lotion in the treatment of xerosis cutis in patients with psoriasis.
  March-June 1992

- Low dose intravenous photofrin photodynamic therapy of psoriasis.
  February 1991-June 1992

- The role of serum growth factors in skin disease. November 1990-June1992

- Comparison of AGN 190168 0.1% and 0.5% gels applied once daily and twice daily in the treatment of psoriasis. November 1991-March 1992

- Intralesional methotrexate therapeutic implants for the treatment of psoriasis.
  July1991-April 1992

- A double blind, randomized, placebo-controlled study of the safety and efficacy of topical Premarin cream to improve the appearance of aging facial skin. July 1991-March 1992

- An open label safety evaluation of adjunctive topical products used by subjects applying Renova in the treatment of photodamage. August 1991-February 1992
- Evaluation of the safety and efficacy of tretinoin emollient cream (TEC-II) 0.05% in the treatment of photodamaged facial skin. July 1990-April 1991
- Double blind vehicle-controlled comparison evaluation of methotrexate in patients with plaque psoriasis. October 1990-April 1991
- Porphyrin affinity towards serum lipoproteins in patients with protoporphyria and porphyria cutanea tarda. January-April 1989